Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 639

1.

Comparison of the current international guidelines on the management of HCC.

Foerster F, Galle PR.

JHEP Rep. 2019 May 28;1(2):114-119. doi: 10.1016/j.jhepr.2019.04.005. eCollection 2019 Aug. Review.

2.

Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system.

Hahn F, Müller L, Mähringer-Kunz A, Schotten S, Düber C, Hinrichs JB, Maschke SK, Galle PR, Bartsch F, Lang H, Weinmann A, Kloeckner R.

PLoS One. 2020 Feb 3;15(2):e0228501. doi: 10.1371/journal.pone.0228501. eCollection 2020.

3.

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR.

J Hepatol. 2020 Feb;72(2):320-341. doi: 10.1016/j.jhep.2019.10.021. Review.

PMID:
31954495
4.

Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.

Mähringer-Kunz A, Wagner F, Hahn F, Weinmann A, Brodehl S, Schotten S, Hinrichs JB, Düber C, Galle PR, Pinto Dos Santos D, Kloeckner R.

Liver Int. 2020 Jan 13. doi: 10.1111/liv.14380. [Epub ahead of print]

PMID:
31943703
5.

Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives.

Nagel M, Labenz C, Wörns MA, Marquardt JU, Galle PR, Schattenberg JM, Nguyen-Tat M.

Health Qual Life Outcomes. 2020 Jan 13;18(1):10. doi: 10.1186/s12955-019-1268-9.

6.

[What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]

Huber Y, Galle PR, Schattenberg JM.

Z Gastroenterol. 2020 Jan;58(1):68-73. doi: 10.1055/a-1068-3981. Epub 2020 Jan 13. Review. German.

PMID:
31931543
7.

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

Michel M, Kalliga E, Labenz C, Straub BK, Wörns MA, Galle PR, Schattenberg JM.

Z Gastroenterol. 2020 Jan;58(1):57-62. doi: 10.1055/a-1062-8788. Epub 2020 Jan 13.

PMID:
31931541
8.

Management of hepatic encephalopathy in Germany: a survey among physicians.

Labenz C, Adarkwah CC, Wörns MA, Miehlke S, Hofmann WP, Buggisch P, Galle PR, Frieling T, Labenz J.

Z Gastroenterol. 2020 Jan;58(1):49-56. doi: 10.1055/a-1010-6974. Epub 2020 Jan 13.

PMID:
31931540
9.

[Monocentric experiences of stereotactic body radiation therapy (SBRT) for advanced hepatocellular carcinomas (BCLC-C)].

Czauderna C, Stockinger M, Ebersberger A, Schmidberger H, Müller L, Kloeckner R, Düber C, Weinmann A, Galle PR, Marquardt JU.

Z Gastroenterol. 2020 Jan;58(1):39-47. doi: 10.1055/a-1072-6683. Epub 2020 Jan 13. German.

PMID:
31931539
10.

Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort.

Vollmar J, Stern F, Lackner K, Mildenberger P, Greif-Higer G, Mittler J, Darstein F, Foerster F, Grimm D, Marquardt JU, Schattenberg J, Woerns MA, Lang H, Galle PR, Zimmermann T.

Z Gastroenterol. 2020 Jan;58(1):30-38. doi: 10.1055/a-1008-9736. Epub 2020 Jan 13.

PMID:
31931538
11.

GASL 2020.

Galle PR.

Z Gastroenterol. 2020 Jan;58(1):29. doi: 10.1055/a-1076-1730. Epub 2020 Jan 13. German. No abstract available.

PMID:
31931537
12.

Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC).

Kaps L, Grambihler A, Yemane B, Nagel M, Labenz C, Ploch P, Michel M, Galle PR, Wörns MA, Schattenberg JM.

Dig Dis Sci. 2019 Dec 18. doi: 10.1007/s10620-019-06009-3. [Epub ahead of print]

PMID:
31853781
13.

Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany.

Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM.

Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]

PMID:
31797186
14.

Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma.

Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A.

Liver Cancer. 2019 Oct;8(5):387-402. doi: 10.1159/000492628. Epub 2018 Oct 4.

15.

Sarcopenia as prognostic factor for survival after orthotopic liver transplantation.

Pinto Dos Santos D, Kloeckner R, Koch S, Hoppe-Lotichius M, Zöller D, Toenges G, Kremer WM, Zimmermann T, Mittler J, Lang H, Düber C, Galle PR, Weinmann A, Sprinzl MF.

Eur J Gastroenterol Hepatol. 2019 Nov 8. doi: 10.1097/MEG.0000000000001552. [Epub ahead of print]

PMID:
31725030
16.

Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol.

Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, Galle PR, Schattenberg JM.

Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.

17.

Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.

Lang H, Baumgart J, Heinrich S, Tripke V, Passalaqua M, Maderer A, Galle PR, Roth W, Kloth M, Moehler M.

Ann Surg. 2019 Nov;270(5):799-805. doi: 10.1097/SLA.0000000000003527.

PMID:
31634180
18.

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy.

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA.

Aliment Pharmacol Ther. 2019 Nov;50(10):1112-1119. doi: 10.1111/apt.15515. Epub 2019 Oct 3.

PMID:
31583743
19.

Health-related quality of life in patients with compensated and decompensated liver cirrhosis.

Labenz C, Toenges G, Schattenberg JM, Nagel M, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Eur J Intern Med. 2019 Dec;70:54-59. doi: 10.1016/j.ejim.2019.09.004. Epub 2019 Sep 14.

PMID:
31530418
20.

Molecular endoscopic imaging: the future is bright.

Ahmed S, Galle PR, Neumann H.

Ther Adv Gastrointest Endosc. 2019 Sep 2;12:2631774519867175. doi: 10.1177/2631774519867175. eCollection 2019 Jan-Dec. Review.

21.

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX.

Liver Int. 2019 Dec;39(12):2214-2229. doi: 10.1111/liv.14223. Epub 2019 Sep 11. Review.

PMID:
31436873
22.

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM.

Aliment Pharmacol Ther. 2019 Oct;50(8):930-939. doi: 10.1111/apt.15427. Epub 2019 Jul 25.

PMID:
31342533
23.

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre.

Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR.

United European Gastroenterol J. 2019 Jul;7(6):838-849. doi: 10.1177/2050640619840221. Epub 2019 Mar 25.

24.

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056.

25.

Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.

Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D, Zimmermann T.

Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G195-G202. doi: 10.1152/ajpgi.00088.2019. Epub 2019 Jun 26.

PMID:
31241979
26.

The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

Hahn F, Müller L, Stöhr F, Mähringer-Kunz A, Schotten S, Düber C, Bartsch F, Lang H, Galle PR, Weinmann A, Kloeckner R.

Liver Int. 2019 Jul;39(7):1307-1314. doi: 10.1111/liv.14132. Epub 2019 May 24.

PMID:
31070868
27.

Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.

Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.

United European Gastroenterol J. 2019 May;7(4):529-537. doi: 10.1177/2050640619825719. Epub 2019 Feb 20.

28.

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases.

Desuki A, Staib F, Gockel I, Moehler M, Lang H, Biesterfeld S, Maderer A, Galle PR, Berger MR, Schimanski CC.

Can J Gastroenterol Hepatol. 2019 Apr 1;2019:2920493. doi: 10.1155/2019/2920493. eCollection 2019.

29.

High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity.

Triantafyllias K, de Blasi M, Lütgendorf F, Cavagna L, Stortz M, Weinmann-Menke J, Konstantinides S, Galle PR, Schwarting A.

Clin Exp Rheumatol. 2019 Nov-Dec;37(6):994-1002. Epub 2019 Apr 2.

PMID:
30943141
30.

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein.

Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M.

Lancet Oncol. 2019 Apr;20(4):e191. doi: 10.1016/S1470-2045(19)30165-2. No abstract available.

PMID:
30942178
31.

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

Zimmermann A, Darstein F, Hoppe-Lotichius M, Toenges G, Lautem A, Abel F, Schad A, Mittler J, Vollmar J, Grimm D, Lang H, Galle PR, Zimmermann T, Schuppan D.

J Gastrointestin Liver Dis. 2019 Mar;28(1):53-61. doi: 10.15403/jgld.2014.1121.281.crr.

32.

Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.

Gehrke N, Biedenbach J, Huber Y, Straub BK, Galle PR, Simon P, Schattenberg JM.

Sci Rep. 2019 Mar 8;9(1):4007. doi: 10.1038/s41598-018-38321-9.

33.

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis.

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA.

Am J Gastroenterol. 2019 May;114(5):764-770. doi: 10.14309/ajg.0000000000000121.

PMID:
30848730
34.

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.

Lautem A, Simon F, Hoppe-Lotichius M, Mittler J, Vollmar J, Schad A, Düber C, Galle PR, Otto G, Zimmermann T, Lang H.

Oncol Rep. 2019 Apr;41(4):2299-2310. doi: 10.3892/or.2019.6995. Epub 2019 Feb 1.

PMID:
30720132
35.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
36.

A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations.

Hofmann M, Thieringer F, Nguyen MA, Månsson W, Galle PR, Langguth P.

Eur J Pharm Biopharm. 2019 Mar;136:192-202. doi: 10.1016/j.ejpb.2019.01.010. Epub 2019 Jan 16.

PMID:
30659894
37.

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.

Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T.

BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7.

38.

Helicobacter pylori Infection as a Risk Factor for Hepatocellular Carcinoma: A Case-Control Study in Ethiopia.

Mekonnen HD, Fisseha H, Getinet T, Tekle F, Galle PR.

Int J Hepatol. 2018 Dec 2;2018:1941728. doi: 10.1155/2018/1941728. eCollection 2018.

39.

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation.

Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-Gómez M, Anstee QM, Schattenberg JM; EPoS Consortium Investigators.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1. doi: 10.1016/j.cgh.2018.12.016. Epub 2018 Dec 20.

PMID:
30580090
40.

Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver.

Czauderna C, Palestino-Dominguez M, Castven D, Becker D, Zanon-Rodriguez L, Hajduk J, Mahn FL, Herr M, Strand D, Strand S, Heilmann-Heimbach S, Gomez-Quiroz LE, Wörns MA, Galle PR, Marquardt JU.

PLoS One. 2018 Dec 21;13(12):e0209067. doi: 10.1371/journal.pone.0209067. eCollection 2018.

41.

Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.

Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann-Heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU.

Int J Cancer. 2019 Jun 1;144(11):2782-2794. doi: 10.1002/ijc.32026. Epub 2018 Dec 14.

PMID:
30485423
42.

[Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease].

Metzger JC, Kurz E, von Spee-Mayer C, Kolck G, Bogumil A, Galle PR, Zimmermann T.

Z Gastroenterol. 2018 Dec;56(12):1507-1512. doi: 10.1055/a-0732-5865. Epub 2018 Nov 22. German.

PMID:
30466133
43.

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy.

Labenz C, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

J Clin Gastroenterol. 2019 Aug;53(7):e303-e307. doi: 10.1097/MCG.0000000000001149.

PMID:
30439761
44.

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

Mähringer-Kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, Schotten S, Hinrichs JB, Graafen D, Pinto Dos Santos D, Galle PR, Kloeckner R.

Liver Int. 2019 Feb;39(2):324-331. doi: 10.1111/liv.13988. Epub 2018 Nov 9.

PMID:
30318826
45.

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.

Tang Y, Reissig S, Glasmacher E, Regen T, Wanke F, Nikolaev A, Gerlach K, Popp V, Karram K, Fantini MC, Schattenberg JM, Galle PR, Neurath MF, Weigmann B, Kurschus FC, Hövelmeyer N, Waisman A.

Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.

PMID:
30315770
46.

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.

Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM.

Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116. doi: 10.1111/apt.14976. Epub 2018 Oct 4.

PMID:
30288767
47.

Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort.

Darstein F, Häuser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, Lang H, Galle PR, Zimmermann T.

Clin Transplant. 2018 Nov;32(11):e13411. doi: 10.1111/ctr.13411. Epub 2018 Oct 27.

PMID:
30230607
48.

Leaving colorectal polyps in place can be achieved with high accuracy using blue light imaging (BLI).

Neumann H, Neumann Sen H, Vieth M, Bisschops R, Thieringer F, Rahman KF, Gamstätter T, Tontini GE, Galle PR.

United European Gastroenterol J. 2018 Aug;6(7):1099-1105. doi: 10.1177/2050640618769731. Epub 2018 May 17.

49.

Feasibility Trial of the Newly Introduced Optical Enhancement Technology in Patients with Gastroesophageal Reflux Disease.

Thomaidis T, Rahman F, Thieringer F, Tontini GE, Mönkemüller K, Ishaq S, Galle PR, Neumann H.

Dig Dis. 2018;36(6):450-455. doi: 10.1159/000490761. Epub 2018 Aug 28.

50.

Guidelines are silver, but a multidisciplinary team discussion may be golden?

Wörns MA, Galle PR.

Liver Int. 2018 Sep;38(9):1550-1551. doi: 10.1111/liv.13936. No abstract available.

PMID:
30145849

Supplemental Content

Loading ...
Support Center